Volitionrx limited announces proof of concept data in lymphoma and leukemia

Volitionrx limited announced results from its latest proof of concept study. a single pre-clinical nu.q™ assay utilizing a basic microtiter plate platform detected 80% of newly diagnosed non-hodgkins lymphoma ("nhl") and leukemia cases (mixture of acute lymphocytic leukemia ("all") and acute myeloid leukemia ("aml") at 95% specificity among healthy subjects. the area under the curve ("auc") for this single assay was 91%. a number of other assays in development also demonstrated promising individual assay results with aucs ranging from 79% to 91%. the objective of this proof of concept study was to investigate a range of cancer conditions not previously studied for detection using nu.q™ assays and the results showed remarkable detection for all 3 blood cancers tested. the next steps are to evaluate these findings in independent larger clinical trials of symptomatic populations using volition's automated elisa product platform whilst also continue pre-analytics studies.
VNRX Ratings Summary
VNRX Quant Ranking